This study presents MAOSS, a multimodal AI model that repurposes non-contrast CT scans and leverages clinical features to detect and stage liver steatosis and fibrosis. Here the authors show MAOSS accurately stratifies cirrhosis progression risk when embedded into the standard clinical workflow, enabling scalable, opportunistic screening for early intervention of steatotic liver disease.
